P. Barthélémy

Publications164
h-index24
Citations1,716
Highly Influential Citations61
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • K. Fizazi
  • 790 Publications, 35,905 Citations
  • T. Choueiri
  • 1,169 Publications, 39,466 Citations
  • R. Motzer
  • 698 Publications, 42,750 Citations
  • M. Grinstaff
  • 436 Publications, 14,590 Citations
  • Publications
  • Influence
Real-Time PCR Assay for Rapid and Accurate Detection of Point Mutations Conferring Resistance to Clarithromycin in Helicobacter pylori
ABSTRACT The main cause of failure of Helicobacter pylori eradication therapy is resistance to clarithromycin. The resistance is due to three point mutations in two positions on the 23S rRNA (A2142C,… Expand
  • 200
  • 14
Prevalence and management of gastroesophageal reflux disease in children and adolescents: a nationwide cross-sectional observational study
This cross-sectional observational study aimed to determine the nationwide prevalence of gastroesophageal reflux disease (GORD) in French children and adolescents. Four hundred four general… Expand
  • 50
  • 4
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
PURPOSE Nivolumab is standard of care for patients with metastatic clear cell renal cell carcinoma (ccRCC) after failure of antiangiogenic therapies, but its activity on brain metastases from ccRCC… Expand
  • 36
  • 4
New Strategies for Medical Management of Castration-Resistant Prostate Cancer
Although advanced prostate cancer patients respond very well to front-line androgen deprivation, failure to hormonal therapy most often occurs after a median time of 18–24 months. The care of… Expand
  • 26
  • 4
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
PURPOSE The aim of this open-label phase II study was to evaluate the activity of raltitrexed (Tomudex; AstraZeneca, Cergy, France) and oxaliplatin combination therapy in patients with diffuse… Expand
  • 121
  • 3
Identification of novel truncated androgen receptor (AR) mutants including unreported pre‐mRNA splicing variants in the 22Rv1 hormone‐refractory prostate cancer (PCa) cell line
Advanced prostate cancer (PCa) has emerged as a public health concern due to population aging. Although androgen deprivation has proven efficacy in this condition, most advanced PCa patients will… Expand
  • 79
  • 3
Adjuvant chemotherapy in elderly patients with early breast cancer. Impact of age and comprehensive geriatric assessment on tumor board proposals.
PURPOSE OF THE STUDY Elderly breast cancer (EBC) patients are often denied adjuvant chemotherapy because of age. Breast cancer is among the most frequent cancer in Western Countries and recent data… Expand
  • 55
  • 3
Accumulation of nanoparticles in “jellyfish” mucus: a bio-inspired route to decontamination of nano-waste
The economic and societal impacts of nano-materials are enormous. However, releasing such materials in the environment could be detrimental to human health and the ecological biosphere. Here we… Expand
  • 27
  • 3
  • PDF
Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
BACKGROUND Nivolumab-ipilimumab demonstrated a survival benefit over sunitinib in first-line setting for metastatic renal cell carcinomas (mRCCs) and is becoming a new standard of care for naïve… Expand
  • 46
  • 2
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.
BACKGROUND This multicenter, phase II, open-label study evaluated the antitumor efficacy and safety of oxaliplatin and raltitrexed (Tomudex) in non-pretreated advanced colorectal cancer patients. … Expand
  • 41
  • 2